Anti-epidermal growth factor receptor-targeted therapy in upper gastrointestinal tract cancers: a meta-analysis
出版年份 2015 全文链接
标题
Anti-epidermal growth factor receptor-targeted therapy in upper gastrointestinal tract cancers: a meta-analysis
作者
关键词
-
出版物
GROWTH FACTORS
Volume 33, Issue 2, Pages 113-127
出版商
Informa UK Limited
发表日期
2015-02-20
DOI
10.3109/08977194.2015.1010643
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Meta-analysis of Six Randomized Control Trials of Chemotherapy Plus Anti-HER Monoclonal Antibody for Advanced Gastric and Gastroesophageal Cancer
- (2014) Huai-Qing Luo et al. Asian Pacific Journal of Cancer Prevention
- Clinicopathological and prognostic significance of circulating tumor cells in patients with gastric cancer: A meta-analysis
- (2014) Xuanzhang Huang et al. INTERNATIONAL JOURNAL OF CANCER
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor
- (2014) June-Koo Lee et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
- (2014) Susan J Dutton et al. LANCET ONCOLOGY
- Results of docetaxel plus oxaliplatin (DOCOX)±cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study
- (2013) Donald Richards et al. EUROPEAN JOURNAL OF CANCER
- Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
- (2013) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
- (2013) Thomas Crosby et al. LANCET ONCOLOGY
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: A meta-analysis
- (2013) Wei Tian et al. PANCREATOLOGY
- Evaluation of the Endorsement of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement on the Quality of Published Systematic Review and Meta-Analyses
- (2013) Nikola Panic et al. PLoS One
- Radiotherapy for gastric cancer: a systematic review and meta-analysis
- (2013) Xiaohui Pang et al. TUMOR BIOLOGY
- Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials
- (2013) Silvy Laporte et al. BMJ Open
- Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
- (2012) Geoffrey Y. Ku et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis
- (2011) Peng Chen et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
- (2010) S. Rao et al. ANNALS OF ONCOLOGY
- Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study
- (2010) M. Moehler et al. ANNALS OF ONCOLOGY
- Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2010) F Lordick et al. BRITISH JOURNAL OF CANCER
- Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations
- (2010) Yelena Y. Janjigian et al. Journal of Thoracic Oncology
- Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
- (2009) S. Lorenzen et al. ANNALS OF ONCOLOGY
- Evidence on the use of platelet-rich plasma for diabetic ulcer: A systematic review
- (2009) Diana Lima Villela et al. GROWTH FACTORS
- Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials
- (2008) Primo N. Lara et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now